IP Library Granted Patent US 9,220,700
Granted Patent B2
US 9,220,700 · App. 13/391,154 · Granted Dec 29, 2015

Cysteine for physiological injection

Inventors: John J. Savarese (Southbury, CT); Paul M. Heerdt (Greenwich, CT)
Assignee: Cornell University
A61K31/198A61K9/0019A61K9/06A61K31/375A61K47/22
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,220,700
App. No.
13/391,154
Granted
Dec 29, 2015
Kind
B2
Abstract

This application describes methods of making and using physiological cysteine solutions useful for reversing a neuromuscular blockade caused by a cysteine-reversible neuromuscular blockade agent, that overcomes problems of cysteine precipitation and dimerization.

Claims (10)

1. A method of reversing a neuromuscular blockade in a patient to whom a cysteine-reversible neuromuscular blockade agent has been administered, comprising administering an effective amount of a physiological solution comprising D-cysteine substantially free of L-cysteine to the patient.

2. A method of reversing a neuromuscular blockade in a patient to whom a cysteine-reversible neuromuscular blockade agent has been administered, comprising administering an effective amount of a physiological solution of cysteine substantially free of L-cysteine to the patient, wherein the physiological solution of cysteine has been made by a method comprising:

adding NaOH and/or a buffering solution to cysteine HCl to generate a 150-250 mg/ml cysteine solution,

wherein the solution is a physiological solution in a volume suitable for intravenous administration over a period of time of about 2 seconds to about 60 seconds.

3. The method of claim 2 , wherein oxygen has been substantially removed from the NaOH or buffering solution.

4. A method of making a cysteine solution for physiological administration, where the method involves:

adding NaOH and/or a buffering solution to cysteine HCl to generate a 150-250 mg/ml cysteine solution,

wherein the solution is a physiological solution in a volume suitable for intravenous administration over a period of time of about 2 seconds to about 60 seconds.

5. The method of claim 2 , wherein the cysteine is D-cysteine.

6. The method of claim 1 , wherein the cysteine is D-cysteine.

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded Dec 16, 2022
From: ATHYRIUM OPPORTUNITIES III ACQUISITION LP
To: SOCIETAL CDMO, INC.
Reel/Frame 062123/0184 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE NAME PREVIOUSLY RECORDED AT REEL: 044166 FRAME: 0008. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY INTEREST. Recorded Mar 8, 2019
From: RECRO PHARMA, INC.
To: ATHYRIUM OPPORTUNITIES III ACQUISITION LP
Reel/Frame 048540/0415 →
SECURITY INTEREST Recorded Nov 17, 2017
From: RECRO PHARMA, INC.
To: ATHYRIUM OPPORTUNITIES III ACQUSITION LP
Reel/Frame 044166/0008 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 15, 2012
From: SAVARESE, JOHN J.; HEERDT, PAUL M.
To: CORNELL UNIVERSITY
Reel/Frame 028215/0105 →
Priority Claims (1)
WO PCT/US2010/000796 · Mar 17, 2010 · international
Continuity (2)
Provisional Application 61235191 · Aug 19, 2009
Related Publication 20120214873A1 · Aug 23, 2012